Olema Oncology

86 articles about Olema Oncology

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 02, 2023

  2/2/2023

  Olema Pharmaceuticals, Inc. announced that the Company granted stock options to four new employees to purchase an aggregate of 97,200 shares of the Company's common stock, effective as of February 1, 2023.

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 04, 2023

  1/4/2023

  Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to three new employees to purchase an aggregate of 54,400 shares of the Company's common stock, effective as of January 3, 2023.

• Olema Oncology to Present at 41st Annual J.P. Morgan Healthcare Conference

  1/3/2023

  Olema Pharmaceuticals, Inc. announced that Sean Bohen, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 11, 2023, at 2:15 p.m. PT.

• Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study

  12/7/2022

  Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, or the “Company”, Nasdaq: OLMA) today announced results from a Phase 1b dose escalation clinical study of OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD), in combination with palbociclib, a CDK 4/6 inhibitor for the treatment of metastatic ER+/HER2- breast cancer.

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2022

  12/2/2022

  Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to two new employees to purchase an aggregate of 62,800 shares of the Company's common stock, effective as of December 1, 2022.

• Olema Oncology Announces Poster Presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS)

  11/21/2022

  Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced two poster presentations on OP-1250, the Company’s complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in development for the treatment of metastatic breast cancer, at the upcoming San Antonio Breast Cancer Symposium (SABCS) meeting being held December 6-10, 2022, at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

• Olema Oncology Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/8/2022

  Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported third quarter financial results for the period ended September 30, 2022, and provided a business update.

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 02, 2022

  11/2/2022

  Olema Pharmaceuticals, Inc. announced that the Company granted stock options to two new employees to purchase an aggregate of 40,400 shares of the Company's common stock, effective as of November 1, 2022.

• Olema Oncology to Present at Upcoming Investor Conferences in November

  11/1/2022

  Olema Pharmaceuticals, Inc. today announced that the Company will present at the following investor conferences in November.

• Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial

  10/26/2022

  Olema Pharmaceuticals, Inc. announced preliminary clinical results from a Phase 1/2 clinical study of OP-1250, the Company’s complete estrogen receptor antagonist and selective ER degrader in development for the treatment of metastatic breast cancer.

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 04, 2022

  10/4/2022

  Olema Pharmaceuticals, Inc. announced that the Company granted stock options to four new employees to purchase an aggregate of 58,300 shares of the Company's common stock, effective as of October 3, 2022.

• Olema Oncology to Present at H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that Shane Kovacs, Chief Operating and Financial Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference.

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 01, 2022

  9/1/2022

  Olema Pharmaceuticals, Inc. announced that the Company granted stock options to three new employees to purchase an aggregate of 72,200 shares of the Company's common stock, effective as of September 1, 2022.

• Olema Oncology Reports Second Quarter 2022 Financial Results and Provides Corporate Update

  8/9/2022

  Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported second quarter financial results for the period ended June 30, 2022, and provided a business update.

• Olema Oncology Advances OP-1250 into Phase 2 Monotherapy Expansion in Patients with ER+/HER2- Advanced Breast Cancer

  8/9/2022

  Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced the advancement of OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), into Phase 2 clinical development for the treatment of ER+/HER2- metastatic breast cancer.

• Olema Oncology to Present at Canaccord Genuity 42nd Annual Growth Conference

  8/4/2022

  Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, announced that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference on Thursday, August 11, 2022 at 1:30 p.m. ET.

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 03, 2022

  8/3/2022

  Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to one new employee to purchase 70,000 shares of the Company's common stock, effective as of August 1, 2022.

• 

  FDA Weekly Review: Avadel, Eton, Pfizer, Celcuity and Others

  7/22/2022

  FDA Weekly Review looks at the FDA's actions related to drug approvals, IND approvals, designations and more. Here’s a look at what happened this week.

• Olema Oncology Receives FDA Fast Track Designation for OP-1250 for the Treatment of ER+ / HER2- Metastatic Breast Cancer

  7/21/2022

  Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to OP-1250.

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 05, 2022

  7/5/2022

  Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, announced that the Company granted stock options to three new employees to purchase an aggregate of 32,000 shares of the Company's common stock, effective as of July 1, 2022.